UroGen Pharma Ltd

NASDAQ:URGN   10:39:41 AM EDT
5.39
+0.22 (+4.26%)
Products

UroGen Announces FDA Clearance Of IND Application For Immunotherapy UGN-301 Intravesical Solution

Published: 03/29/2022 13:25 GMT
UroGen Pharma Ltd (URGN) - Urogen Announces FDA Clearance of Ind Application for the Investigational Immunotherapy Ugn-301 (zalifrelimab) Intravesical Solution in Recurrent Non-muscle Invasive Bladder Cancer.
Urogen Pharma Ltd - Multi-arm Phase 1 Study is Expected to Start in April and Support Development of Ugn-301 in High-grade (hg) Nmibc.